Boehringer trial pairs obrixtamig with Zai Lab's ZL-1310 in SCLC and neuroendocrine cancersNov 12Trial updateBoehringer IngelheimZai Lab (Shanghai) Co., Ltd.
Zai Lab discloses $249.9 million private securities offering in SEC Form DNov 9FinancingZai Lab (Shanghai) Co., Ltd.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Zai Lab raises $250 million via private placement, discloses new zoci dataOct 23FinancingZai Lab (Shanghai) Co., Ltd.
Zai Lab registers Phase 3 trial for ZL-1310 in lung cancer and real-world KarXT study in ChinaSep 3Weekly roundup, 2 itemsxanomeline and trospium chlorideZai Lab (Shanghai) Co., Ltd.
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestonesAug 6Quarterly updateZai Lab (Shanghai) Co., Ltd.ZL-1503
Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig with Zai Lab's ZL-1310 in SCLCJul 16Trial updateBoehringer IngelheimZai Lab (Shanghai) Co., Ltd.